Last reviewed · How we verify

Nurofen Plus® — Competitive Intelligence Brief

Nurofen Plus® (Nurofen Plus®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID/opioid combination analgesic. Area: Pain Management.

phase 3 NSAID/opioid combination analgesic COX-1/COX-2 (ibuprofen); mu opioid receptor (codeine) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Nurofen Plus® (Nurofen Plus®) — Reckitt Benckiser LLC. Nurofen Plus combines ibuprofen (a nonsteroidal anti-inflammatory drug) with codeine phosphate (an opioid analgesic) to provide enhanced pain relief through dual analgesic and anti-inflammatory action.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Nurofen Plus® TARGET Nurofen Plus® Reckitt Benckiser LLC phase 3 NSAID/opioid combination analgesic COX-1/COX-2 (ibuprofen); mu opioid receptor (codeine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID/opioid combination analgesic class)

  1. Reckitt Benckiser LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nurofen Plus® — Competitive Intelligence Brief. https://druglandscape.com/ci/nurofen-plus. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: